nod1.jpg 

Infectious Diseases

Therapeutic potential of inosine pranobex in enhancing non-specific antiviral protection in patients with COVID-19

The defense mechanisms of the human body determine non-specific resistance of non-immune cells that comprise the majority of cells in the organism and are exposed to various environmental factors (such as radiation, pollutants, microbial infection), as well as innate and acquired immunity aimed at enhancing the response to external (and internal) stimuli. Inosine is one of the drugs that can strengthen the internal protective reserves of non-immune cells of the human body, primarily against various viruses. Inosine in the form of inosine pranobex is the main component of Groprinosin (Gedeon Richter Pharma LLC). It was shown that protective effect of inosine is attributed to its interaction with the surface adenosine A2A receptor from the family of G-protein-coupled receptors, with activation of the peroxisome proliferator-activated receptor gamma (PPAR-g). This results in inhibition of the mevalonate pathway of cholesterol synthesis and restriction of the viral life cycle of both enveloped (herpes viruses, hepatitis, dengue, mumps, influenza, Ebola, coronaviruses SARS-CoV, MERS-CoV, SARS-CoV-2) and non-enveloped (adenovirus, enterovirus, such as Coxsackie, rotavirus) viruses. Therefore, inosine can be included into the existing clinical protocols or used as an alternative to improve treatment efficacy.
Key words: non-specific resistance, inosine pranobex, groprinosine, SARS-CoV-2, COVID-19, adenosine A2A receptor
For citation: Isakov D.V., Isakov V.A. Therapeutic potential of inosine pranobex in enhancing non-specific antiviral protection in patients with COVID-19. Infekc. bolezni (Infectious diseases). 2021; 19(4): 92–96. (In Russian). DOI: 10.20953/1729-9225-2021-4-92–96

Open access

Яндекс.Метрика